USD
+$0.00
(+0.00%
)At Close (As of Nov 26, 2025)
$9.05M
Market Cap
-
P/E Ratio
-6.71
EPS
$13.29
52 Week High
$0.95
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$823K |
| Total Revenue | $0 |
| Cost Of Revenue | $823K |
| Costof Goods And Services Sold | $823K |
| Operating Income | -$16M |
| Selling General And Administrative | $4.1M |
| Research And Development | $8.4M |
| Operating Expenses | $16M |
| Investment Income Net | - |
| Net Interest Income | $179K |
| Interest Income | $184K |
| Interest Expense | $5K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $823K |
| Income Before Tax | -$16M |
| Income Tax Expense | -$16M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$16M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$16M |
| Ebitda | -$15M |
| Net Income | -$16M |
| Field | Value (USD) |
|---|---|
| Total Assets | $9.3M |
| Total Current Assets | $8.6M |
| Cash And Cash Equivalents At Carrying Value | $6.8M |
| Cash And Short Term Investments | $6.8M |
| Inventory | - |
| Current Net Receivables | $402K |
| Total Non Current Assets | $702K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $1.4M |
| Other Non Current Assets | - |
| Total Liabilities | $13M |
| Total Current Liabilities | $13M |
| Current Accounts Payable | $7.5M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $456K |
| Total Non Current Liabilities | $572K |
| Capital Lease Obligations | $878K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $878K |
| Other Current Liabilities | $4.7M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$3.9M |
| Treasury Stock | - |
| Retained Earnings | -$397M |
| Common Stock | $5K |
| Common Stock Shares Outstanding | $6.1M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$11M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $823K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $11M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $611K |
| Dividend Payout Common Stock | $611K |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$16M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$823K |
| Total Revenue | $0 |
| Cost Of Revenue | $823K |
| Costof Goods And Services Sold | $823K |
| Operating Income | -$16M |
| Selling General And Administrative | $4.1M |
| Research And Development | $8.4M |
| Operating Expenses | $16M |
| Investment Income Net | - |
| Net Interest Income | $179K |
| Interest Income | $184K |
| Interest Expense | $5K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $823K |
| Income Before Tax | -$16M |
| Income Tax Expense | -$16M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$16M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$16M |
| Ebitda | -$15M |
| Net Income | -$16M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Mustang Bio, Inc. (ticker: MBIO) is a clinical-stage biopharmaceutical company based in Worcester, Massachusetts, dedicated to advancing innovative cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic disorders. The company is focused on developing a robust pipeline that leverages cutting-edge technologies with the potential for curative outcomes. Committed to tackling significant unmet medical needs, Mustang Bio strives to transform the treatment landscape through strategic collaborations and a strong emphasis on gene editing innovation, positioning itself as a key player in the biotherapeutics industry.